Page 5 of 13
AUTHOR CONTRIBUTIONS
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
The manuscript was written through contributions of all authors.
All authors have given approval to the final version of the manuꢀ
script.
ACKNOWLEDGMENTS
The authors thank Beverly Ellis for her assistance with mouse
blood collection. The authors thank Dr. Cody Wenthur and Dr.
Paul Bremer for helpful discussions. This work was supported by
generous funding from NIDA (R01 DA008590 to KDJ and F32
DA044692 to MEO.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
REFERENCES
1
.
U.S. Department of Health and Human Services
1
5.
Van Dyke, C.; Barash, P. G.; Jatlow, P.; Byck, R.
(
HHS), Office of the Surgeon General. Facing addiction in America:
Cocaine: plasma concentrations after intranasal application in man.
Science 1976, 191, 859ꢀ861.
The Surgeon General's report on alcohol, drugs, and health.,
Washington, DC: HHS, 2016.
1
6.
of cocaine in man. Clin. Pharmacol. Ther. 1978, 23, 547ꢀ552.
7. Carrera, M. R.; Ashley, J. A.; Parsons, L. H.;
Inaba, T.; Stewart, D. J.; Kalow, W. Metabolism
2.
Drug Abuse Warning Network (DAWN), 2011
(ICPSR 34565), HHS Publication No. (SMA) 13ꢀ4760, DAWN Series
Dꢀ39. Rockville, MD. 2011.
1
Wirsching, P.; Koob, G. F.; Janda, K. D. Suppression of psychoactive
effects of cocaine by active immunization. Nature 1995, 378, 727ꢀ730.
3
.
Behavioral Health Trends in the United States:
Results from the 2014 National Survey on Drug Use and Health.
NSDUH Series Hꢀ44, HHS Publication No. (SMA) 15−4927;
Substance Abuse and Mental Health Services Administration:
Rockville, MD. 2015.
1
8.
Cai, X. Q.; Whitfield, T.; Moreno, A. Y.; Grant,
Y.; Hixon, M. S.; Koob, G. F.; Janda, K. D. Probing the effects of
hapten stability on cocaine vaccine immunogenicity. Mol. Pharm.
013, 10, 4176ꢀ4184.
2
4
.
Karila, L.; Reynaud, M.; Aubin, H. J.; Rolland,
19.
Maoz, A.; Hicks, M. J.; Vallabhjosula, S.; Synan,
B.; Guardia, D.; Cottencin, O.; Benyamina, A. Pharmacological
treatments for cocaine dependence: is there something new? Curr.
Pharm. Des. 2011, 17, 1359ꢀ1368.
M.; Kothari, P. J.; Dyke, J. P.; Ballon, D. J.; Kaminsky, S. M.; De, B.
P.; Rosenberg, J. B.; Martinez, D.; Koob, G. F.; Janda, K. D.; Crystal,
R. G. Adenovirus capsidꢀbased antiꢀcocaine vaccine prevents cocaine
from binding to the nonhuman primate CNS dopamine transporter.
Neuropsychopharmacology 2013, 38, 2170ꢀ2178.
5.
Loftis, J. M.; Huckans, M. Substance use
disorders: psychoneuroimmunological mechanisms and new targets
for therapy. Pharmacol. Ther. 2013, 139, 289ꢀ300.
20.
Hicks, M. J.; Kaminsky, S. M.; De, B. P.;
6
.
Moreno, A. Y.; Janda, K. D. Current challenges
Rosenberg, J. B.; Evans, S. M.; Foltin, R. W.; Andrenyak, D. M.;
Moody, D. E.; Koob, G. F.; Janda, K. D.; Ricart Arbona, R. J.;
Lepherd, M. L.; Crystal, R. G. Fate of systemically administered
cocaine in nonhuman primates treated with the dAd5GNE anticocaine
vaccine. Hum. Gene Ther. Clin. Dev. 2014, 25, 40ꢀ49.
for the creation of effective vaccines against drugs of abuse. Expert
Rev. Vaccines 2011, 10, 1637ꢀ1639.
7
.
Janda, K. D.; Treweek, J. B. Vaccines targeting
drugs of abuse: is the glass halfꢀempty or halfꢀfull? Nat. Rev. Immunol.
011, 12, 67ꢀ72.
2
2
1.
Evans, S. M.; Foltin, R. W.; Hicks, M. J.;
8
.
Haney, M.; Gunderson, E. W.; Jiang, H. P.;
Rosenberg, J. B.; De, B. P.; Janda, K. D.; Kaminsky, S. M.; Crystal, R.
G. Efficacy of an adenovirusꢀbased antiꢀcocaine vaccine to reduce
cocaine selfꢀadministration and reacqusition using a choice procedure
in rhesus macaques. Pharmacol. Biochem. Behav. 2016, 150-151, 76ꢀ
86.
Collins, E. D.; Foltin, R. W. Cocaineꢀspecific antibodies blunt the
subjective effects of smoked cocaine in humans. Biol Psychiat 2010,
6
7, 59ꢀ65.
9
.
Martell, B. A.; Mitchell, E.; Poling, J.; Gonsai,
K.; Kosten, T. R. Vaccine pharmacotherapy for the treatment of
cocaine dependence. Biol. Psychiatry 2005, 58, 158ꢀ164.
2
2.
De, B. P.; Pagovich, O. E.; Hicks, M. J.;
Rosenberg, J. B.; Moreno, A. Y.; Janda, K. D.; Koob, G. F.; Worgall,
S.; Kaminsky, S. M.; Sondhi, D.; Crystal, R. G. Disrupted adenovirusꢀ
based vaccines against small addictive molecules circumvent antiꢀ
adenovirus immunity. Hum. Gene Ther. 2013, 24, 58ꢀ66.
10.
Martell, B. A.; Orson, F. M.; Poling, J.; Mitchell,
E.; Rossen, R. D.; Gardner, T.; Kosten, T. R. Cocaine vaccine for the
treatment of cocaine dependence in methadoneꢀmaintained patients: a
randomized, doubleꢀblind, placeboꢀcontrolled efficacy trial. Arch.
Gen. Psychiatry 2009, 66, 1116ꢀ1123.
2
3.
Hicks, M. J.; De, B. P.; Rosenberg, J. B.;
Davidson, J. T.; Moreno, A. Y.; Janda, K. D.; Wee, S.; Koob, G. F.;
Hackett, N. R.; Kaminsky, S. M.; Worgall, S.; Toth, M.; Mezey, J. G.;
Crystal, R. G. Cocaine analog coupled to disrupted adenovirus: a
vaccine strategy to evoke highꢀtiter immunity against addictive drugs.
Mol. Ther. 2011, 19, 612ꢀ619.
11.
Kosten, T. R.; Domingo, C. B.; Shorter, D.;
Orson, F.; Green, C.; Somoza, E.; Sekerka, R.; Levin, F. R.; Mariani,
J. J.; Stitzer, M.; Tompkins, D. A.; Rotrosen, J.; Thakkar, V.; Smoak,
B.; Kampman, K. Vaccine for cocaine dependence: a randomized
doubleꢀblind placeboꢀcontrolled efficacy trial. Drug Alcohol Depend.
2014, 140, 42ꢀ47.
2
4.
Koob, G.; Hicks, M. J.; Wee, S.; Rosenberg, J.
B.; De, B. P.; Kaminsky, S. M.; Moreno, A.; Janda, K. D.; Crystal, R.
G. Antiꢀcocaine vaccine based on coupling a cocaine analog to a
disrupted adenovirus. CNS Neurol. Disord. Drug Targets 2011, 10,
899ꢀ904.
12.
Kosten, T. R.; Rosen, M.; Bond, J.; Settles, M.;
St Clair Roberts, J.; Shields, J.; Jack, L.; Fox, B. Human therapeutic
cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20, 1196ꢀ
1
204.
2
5.
Rosenberg, J. B.; Hicks, M. J.; De, B. P.;
1
3.
Carrera, M. R.; Ashley, J. A.; Wirsching, P.;
Pagovich, O.; Frenk, E.; Janda, K. D.; Wee, S.; Koob, G. F.; Hackett,
N. R.; Kaminsky, S. M.; Worgall, S.; Tignor, N.; Mezey, J. G.;
Crystal, R. G. AAVrh.10ꢀmediated expression of an antiꢀcocaine
antibody mediates persistent passive immunization that suppresses
cocaineꢀinduced behavior. Hum. Gene Ther. 2012, 23, 451ꢀ459.
Koob, G. F.; Janda, K. D. A secondꢀgeneration vaccine protects
against the psychoactive effects of cocaine. Proc. Natl. Sci. Acad. U.
S. A. 2001, 98, 1988ꢀ1992.
1
4.
Sakurai, M.; Wirsching, P.; Janda, K. D. Design
and synthesis of a cocaineꢀdiamide hapten for vaccine development.
Tetrahedron Lett. 1996, 37, 5479ꢀ5482.
ACS Paragon Plus Environment